Chelsea Bahney
PhD Principal Investigator
Bone Repair & Regenerative Therapeutics
Nexocura is a patented smart drug delivery system that provides patients with a solution for safe, fast, and nonsurgical bone fracture healing by stimulating natural pathways.
About 5-10% of bone fractures heal poorly, and that number rises to 50% for patients with comorbidities. Specifically, a patient’s fracture is designated as a delayed union if the bone has not healed between three and six months after surgical intervention. This is the point in time when patients need a solution to help their fracture properly repair.
Nexocura is a combination of a proprietary growth factor in an advanced microdelivery system. The growth factor stimulates cartilage and bone to accelerate fracture repair, and the delivery system allows for sustained release in the localized target site.
Our team conducted a survey among 28 orthopedic surgeons to get direct feedback from key opinion leaders and confirm the market opportunity. We investigated the manufacturing process of our combination product and identified the regulatory pathway.
PhD Principal Investigator
Bone Repair & Regenerative Therapeutics
B.S. in Pharmaceutical Sciences & Drug Design
Purdue University
B.S. Biomedical Engineering
Cal Poly SLO
B.S. in Neuroscience
Colorado College
B.S. in Bioengineering
UC Berkeley
M.B.A.
USC